Login to Your Account

ImmuPharma Restarts Lupus Work; $76M Loan for Phase III

By Nuala Moran
Staff Writer

Wednesday, May 29, 2013
LONDON – Following an 18-month hiatus, ImmuPharma plc can now proceed with Phase III development of its lupus treatment, Lupuzor, after agreeing to a £50 million (US$75.7 million) loan to finance the trial.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription